West Pharmaceutical Services (NYSE:WST) Updates FY 2025 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 6.000-6.200 for the period, compared to the consensus EPS estimate of 7.430. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $3.0 billion.

West Pharmaceutical Services Stock Up 7.9 %

WST opened at $214.84 on Friday. West Pharmaceutical Services has a fifty-two week low of $197.01 and a fifty-two week high of $400.88. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.23 and a current ratio of 3.00. The stock has a market cap of $15.56 billion, a price-to-earnings ratio of 31.87, a price-to-earnings-growth ratio of 19.31 and a beta of 1.01. The firm’s fifty day moving average is $327.86 and its 200 day moving average is $313.82.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, February 13th. The medical instruments supplier reported $1.82 EPS for the quarter, beating the consensus estimate of $1.75 by $0.07. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. On average, sell-side analysts forecast that West Pharmaceutical Services will post 6.67 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, February 11th. Stockholders of record on Friday, February 7th were given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend was Friday, February 7th. West Pharmaceutical Services’s payout ratio is currently 12.46%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on WST shares. Citigroup assumed coverage on shares of West Pharmaceutical Services in a research report on Wednesday, January 8th. They set a “buy” rating and a $400.00 target price for the company. Deutsche Bank Aktiengesellschaft raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price objective for the company in a report on Friday. StockNews.com raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Tuesday. KeyCorp dropped their price target on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a research note on Friday. Finally, Bank of America lifted their price objective on West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $344.00.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.